| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 64 | 2024 | 774 | 11.090 |
Why?
|
| Down Syndrome | 25 | 2025 | 198 | 7.010 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 129 | 2.860 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 86 | 2.270 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2023 | 520 | 2.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 1244 | 1.730 |
Why?
|
| Leukemia | 6 | 2023 | 367 | 1.420 |
Why?
|
| Child | 88 | 2025 | 24606 | 1.210 |
Why?
|
| Methotrexate | 10 | 2024 | 336 | 1.200 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1157 | 0.970 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 42 | 0.930 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 185 | 0.930 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 28 | 0.920 |
Why?
|
| Disease-Free Survival | 16 | 2024 | 880 | 0.910 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 2 | 0.860 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 1714 | 0.860 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 40 | 0.840 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 118 | 0.840 |
Why?
|
| Prognosis | 26 | 2024 | 4686 | 0.810 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 121 | 0.790 |
Why?
|
| Humans | 111 | 2025 | 125358 | 0.780 |
Why?
|
| Child, Preschool | 40 | 2025 | 14145 | 0.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1097 | 0.680 |
Why?
|
| Penetrance | 1 | 2020 | 102 | 0.680 |
Why?
|
| Lymphoma | 1 | 2023 | 318 | 0.650 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 158 | 0.640 |
Why?
|
| Integrases | 1 | 2020 | 160 | 0.640 |
Why?
|
| Receptors, Cytokine | 4 | 2024 | 69 | 0.640 |
Why?
|
| Infant | 30 | 2024 | 12601 | 0.640 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2024 | 49 | 0.630 |
Why?
|
| Adolescent | 36 | 2024 | 19423 | 0.610 |
Why?
|
| Mycoses | 2 | 2021 | 118 | 0.580 |
Why?
|
| Gene Rearrangement | 4 | 2024 | 323 | 0.560 |
Why?
|
| Salvage Therapy | 1 | 2019 | 185 | 0.550 |
Why?
|
| Acute Disease | 8 | 2023 | 1097 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 733 | 0.510 |
Why?
|
| Male | 57 | 2025 | 61561 | 0.500 |
Why?
|
| Young Adult | 20 | 2024 | 9058 | 0.480 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 532 | 0.480 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 131 | 0.470 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1694 | 0.470 |
Why?
|
| Recurrence | 9 | 2024 | 1394 | 0.460 |
Why?
|
| Female | 56 | 2025 | 66815 | 0.460 |
Why?
|
| Remission Induction | 2 | 2012 | 292 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 2656 | 0.440 |
Why?
|
| Self Report | 1 | 2017 | 508 | 0.440 |
Why?
|
| Transcription Factors | 3 | 2020 | 2603 | 0.430 |
Why?
|
| Mutation | 9 | 2023 | 5904 | 0.430 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1756 | 0.400 |
Why?
|
| Steroids | 1 | 2013 | 202 | 0.390 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 264 | 0.370 |
Why?
|
| Bacterial Infections | 1 | 2014 | 307 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3176 | 0.360 |
Why?
|
| Gene Deletion | 3 | 2021 | 793 | 0.350 |
Why?
|
| Treatment Failure | 1 | 2012 | 338 | 0.350 |
Why?
|
| DNA Methylation | 3 | 2021 | 1051 | 0.350 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2373 | 0.350 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 620 | 0.350 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 235 | 0.340 |
Why?
|
| Genomics | 5 | 2024 | 1520 | 0.320 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 4 | 0.320 |
Why?
|
| Dasatinib | 2 | 2020 | 41 | 0.310 |
Why?
|
| Metabolome | 2 | 2021 | 293 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 394 | 0.280 |
Why?
|
| Histones | 1 | 2011 | 542 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2020 | 273 | 0.280 |
Why?
|
| Point Mutation | 1 | 2008 | 351 | 0.280 |
Why?
|
| Neoplasms | 5 | 2024 | 2799 | 0.270 |
Why?
|
| Metabolomics | 2 | 2021 | 422 | 0.270 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 277 | 0.240 |
Why?
|
| Mice | 11 | 2024 | 17750 | 0.240 |
Why?
|
| Leukapheresis | 1 | 2025 | 14 | 0.240 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12287 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2024 | 678 | 0.240 |
Why?
|
| Genotype | 6 | 2021 | 2570 | 0.240 |
Why?
|
| Microfluidics | 1 | 2025 | 22 | 0.240 |
Why?
|
| Osteosarcoma | 1 | 2008 | 255 | 0.230 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.230 |
Why?
|
| Exome | 3 | 2022 | 1034 | 0.230 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16363 | 0.230 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3313 | 0.220 |
Why?
|
| Survival Rate | 7 | 2021 | 2050 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 38 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.220 |
Why?
|
| Mercaptopurine | 3 | 2019 | 71 | 0.220 |
Why?
|
| Animals | 15 | 2025 | 34318 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 114 | 0.210 |
Why?
|
| Risk Factors | 10 | 2025 | 10296 | 0.210 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 13 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 115 | 0.210 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 427 | 0.210 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5171 | 0.210 |
Why?
|
| Bone Marrow | 2 | 2022 | 323 | 0.210 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 45 | 0.200 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 2061 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 144 | 0.200 |
Why?
|
| Immunoglobulins | 1 | 2023 | 173 | 0.200 |
Why?
|
| Adult | 14 | 2025 | 29540 | 0.190 |
Why?
|
| Gene Frequency | 2 | 2021 | 729 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 140 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 345 | 0.190 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 81 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 177 | 0.180 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.180 |
Why?
|
| Alleles | 3 | 2021 | 1618 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 22 | 0.180 |
Why?
|
| Research Design | 1 | 2025 | 694 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 109 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2024 | 724 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 57 | 0.170 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 12 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 161 | 0.170 |
Why?
|
| Incidence | 6 | 2024 | 3133 | 0.170 |
Why?
|
| Leukocyte Count | 3 | 2025 | 250 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 505 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 18 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 66 | 0.170 |
Why?
|
| Software | 1 | 2024 | 687 | 0.170 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 42 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 81 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 287 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 260 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 19 | 0.160 |
Why?
|
| Social Class | 1 | 2020 | 190 | 0.160 |
Why?
|
| Karyotyping | 4 | 2015 | 323 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 3420 | 0.150 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 27 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 548 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2021 | 364 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1362 | 0.150 |
Why?
|
| Diploidy | 2 | 2008 | 37 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 565 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 187 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2021 | 739 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 306 | 0.150 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8273 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 66 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2020 | 186 | 0.150 |
Why?
|
| Maternal Exposure | 1 | 2019 | 149 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2019 | 102 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 94 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 229 | 0.140 |
Why?
|
| Registries | 2 | 2022 | 1434 | 0.140 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 860 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 57 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1909 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 681 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 538 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1104 | 0.130 |
Why?
|
| Genome, Human | 2 | 2021 | 1292 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2020 | 547 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 649 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 703 | 0.130 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 114 | 0.130 |
Why?
|
| Cell Line | 3 | 2013 | 2756 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2021 | 826 | 0.130 |
Why?
|
| Base Sequence | 2 | 2011 | 3111 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2024 | 3431 | 0.120 |
Why?
|
| Risk | 2 | 2023 | 759 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 35 | 0.120 |
Why?
|
| Smad Proteins | 1 | 2015 | 42 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 331 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 736 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 772 | 0.120 |
Why?
|
| Biomarkers | 2 | 2021 | 3106 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 264 | 0.120 |
Why?
|
| Apoptosis | 2 | 2018 | 1818 | 0.120 |
Why?
|
| DNA | 1 | 2020 | 1621 | 0.110 |
Why?
|
| Dexamethasone | 3 | 2021 | 272 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2024 | 4828 | 0.110 |
Why?
|
| Texas | 5 | 2022 | 3581 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 384 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 1065 | 0.110 |
Why?
|
| Dendritic Cells | 2 | 2013 | 414 | 0.110 |
Why?
|
| Age Factors | 3 | 2021 | 2818 | 0.110 |
Why?
|
| Heart Defects, Congenital | 1 | 2025 | 1832 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 327 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 855 | 0.100 |
Why?
|
| Cytosol | 1 | 2013 | 162 | 0.100 |
Why?
|
| Electronics | 2 | 2023 | 43 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 28 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 465 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 573 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 617 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 418 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 325 | 0.100 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 163 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 135 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 257 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 63 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 420 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 394 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 746 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 286 | 0.090 |
Why?
|
| Immunophenotyping | 3 | 2019 | 327 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 413 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 306 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 657 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1240 | 0.080 |
Why?
|
| Nitriles | 2 | 2024 | 146 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 199 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1495 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 278 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 41 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 49 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 290 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 95 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 578 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 1077 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 664 | 0.080 |
Why?
|
| Vincristine | 2 | 2021 | 191 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 508 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 240 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 288 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 63 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2024 | 377 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 802 | 0.070 |
Why?
|
| Gene Editing | 2 | 2021 | 186 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 626 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 772 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 653 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 1253 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 821 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 605 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4423 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2718 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 47 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1275 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 13 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1592 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1720 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 230 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1802 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2096 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2008 | 887 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 185 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 212 | 0.050 |
Why?
|
| France | 1 | 2023 | 80 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 27 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 9 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 176 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 33 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 220 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1763 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 42 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2182 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 650 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 456 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2252 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1243 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 914 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1033 | 0.050 |
Why?
|
| Transcriptome | 2 | 2019 | 977 | 0.050 |
Why?
|
| Entropy | 1 | 2021 | 26 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2021 | 35 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 6 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 49 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 39 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1534 | 0.040 |
Why?
|
| United States | 3 | 2021 | 10908 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 907 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 32 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 352 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 35 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 244 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 484 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 126 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 578 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 35 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 132 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 217 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 57 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 105 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 869 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3754 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 107 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 19 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 283 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 142 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 215 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 781 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 102 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 518 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 439 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 291 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 766 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 343 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 544 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4270 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 115 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 66 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1027 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 359 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 246 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3729 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 19 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 168 | 0.040 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 21 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 207 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 155 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 572 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 6142 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 564 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 63 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 634 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1400 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 20 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 40 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 174 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 668 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2022 | 4595 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 385 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 819 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1363 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 412 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 300 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 832 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1189 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 299 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 875 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 683 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 256 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 586 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 1909 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 163 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 139 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 130 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1633 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 530 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 32 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 779 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 680 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 95 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 70 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 48 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1982 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1707 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 528 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1505 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 118 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 80 | 0.030 |
Why?
|
| Epilepsy | 1 | 2020 | 874 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 214 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 144 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 725 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1639 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4409 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 670 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 825 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 621 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1692 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2414 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 505 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 762 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1158 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1427 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 483 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2056 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1756 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 963 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1961 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2880 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 3044 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 26765 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 19727 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 688 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2525 | 0.010 |
Why?
|